Sun Pharmaceutical Industries has agreed to buy US-listed Organon & Co. for $14 per share in an all-cash deal worth $11.75 billion (roughly Rs 97,500 crore), making it one of the largest overseas acquisitions by an Indian pharma company. Organon was spun off from Merck in 2021 and sells more than 70 products across women's health, general medicines, and biosimilars in 140 countries. Its 2025 revenue stood at $6.2 billion, with adjusted EBITDA of $1.9 billion, though it carries $8.6 billion in debt. Sun Pharma will fund the deal through internal cash and committed bank financing. Post-merger, the combined company will have revenue of $12.4 billion and presence in 150 countries, pushing Sun Pharma into the global top 25 pharma firms. EBITDA and cash flows are expected to nearly double, though the deal leaves net debt at 2.3x EBITDA at closing. The deal gives Sun Pharma an immediate foothold in biosimilars as a top-10 global player and makes it a top-3 company in women's health worldwide. Innovative medicines will account for 27% of combined revenue. Both boards have approved the transaction, which still needs regulatory clearances and Organon shareholder approval. Closing is expected in early 2027.
Flipkart will launch a food delivery pilot in Bengaluru by mid-August, charging restaurants a 10-11% commission compared to the 25-35% levied by Swiggy and Zomato. The move targets growing restaurant discontent with incumbent platforms and aims to drive daily engagement across Flipkart's 500 million registered users.
Maruti Suzuki crossed two lakh domestic units in July 2026 for the first time, recording 42.4% year-on-year growth. Total sales including exports and OEM supplies reached 2,41,421 units, with all passenger vehicle segments posting gains.
Air India's net loss more than doubled to ₹22,238 crore in FY26, prompting Tata Sons chairman N Chandrasekaran to extend the Vihaan.AI turnaround timeline from five years to as long as a decade.
UpGrad's all-stock acquisition of Unacademy, valued at Rs 1,955 crore, is set to close within three weeks after CCI clearance and near-complete investor sign-offs. The deal combines upGrad's upskilling business with Unacademy's test prep and medical education platforms, with Gaurav Munjal staying on as CEO.
